Ash A. Alizadeh, MD/PhD
Academic Appointments
- Assistant Professor, Medicine - Oncology
- Member, Stanford Cancer Institute
- Member, Child Health Research Institute
- Member, Bio-X
Key Documents
Contact Information
-
Clinical Offices
Stanford Comprehensive Cancer Center 875 Blake Wilbur Dr MC 5820 Stanford, CA 94305 Tel Work (650) 498-6000 Fax (650) 724-5203
- Academic Offices
Personal Information EmailAlternate Contact Deanne Daly Administrative Assistant Email Tel Work 650-725-6423Not for medical emergencies or patient use
Professional Overview
Clinical Focus
- Oncology
- Lymphoma
- B-Cell Chronic Lymphocytic Leukemia
- Waldenstrom Macroglobulinemia
- Burkitt Lymphoma
Honors and Awards
- Doris Duke Clinical Scientist Development Award, Stanford University (2011)
- Bent & Janet Cardan Oncology Research Fellow, Stanford University (2010)
- Josephine Q. Berry Faculty Scholar in Cancer Research, Stanford University (2010)
- Clinical Investigator Program: Fellow Award, Stanford University Medical Center (2004-2010)
- Leukemia & Lymphoma Society Special Fellow in Clinical Research, Stanford University (2010)
Professional Education
| Board Certification: | Oncology, American Board of Internal Medicine (2009) |
| Board Certification: | Hematology, American Board of Internal Medicine (2009) |
| Board Certification: | American Board of Internal Medicine, Hematology (2009) |
| Board Certification: | American Board of Internal Medicine, Medical Oncology (2009) |
| Fellowship: | Stanford University School of Medicine, CA USA (2009) |
Postdoctoral Advisees
Graduate & Fellowship Program Affiliations
Internet Links
Scientific Focus
Current Research Interests
My research is focused on attaining a better understanding of the initiation, maintenance, and progression of lymphoid tumors, and their response to immunochemotherapy toward improving current treatment strategies.
In this effort, I employ tools from functional genomics, computational biology, molecular genetics, and mouse models. I hope to apply this knowledge towards the design of clinical trials in the treatment of patients with lymphoma, leukemia, and myeloma.
Clinical Trials
Publications
- Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. JAMA. 2010; (24): 2706-15
- Therapeutic Antibody Targeting of CD47 Synergizes with Rituximab to Completely Eradicate Human B-Cell Lymphoma Cell. 2010; (5): 699-713
- CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009; (2): 286-99
- Molecular outcome prediction in diffuse large-B-cell lymphoma. N Engl J Med. 2009; (26): 2794-5
- SOURCE: a unified genomic resource of functional annotations, ontologies, and gene expression data. Nucleic Acids Res. 2003; (1): 219-23
Help